Enhanced skin penetration of Finasteride loaded DMSO-liposomes for the treatment of androgenic alopecia : comparison with conventional liposomes
Long-term treatment with finasteride (FIN) for androgenic alopecia is restricted due to its systemic side effects. To address this problem, DMSO-modified liposomes were prepared in the present study to improve the topical delivery of FIN. DMSO-liposomes were prepared by a modification of the ethanol injection method. It was hypothesized that the permeation-enhancing property of DMSO could promote drug delivery to deeper skin layer where hair follicles are present. Liposomes were optimized by quality by design (QbD) approach and biologically evaluated in a rat model of testosterone-induced alopecia. Optimized DMSO-liposomes were spherical and had mean vesicle size, zeta potential, and entrapment efficiency of 330.1 ± 1.5, -14.52 ± 1.32, and 59.02 ± 1.12%, respectively. Biological evaluation on testosterone-induced alopecia and skin histology shows that follicular density and anagen/telogen (A/T) ratio were increased in rats treated with DMSO-liposomes as compared to FIN-liposomes without DMSO and an alcoholic solution of FIN applied topically. DMSO-liposomes could be promising skin delivery vehicles for FIN or similar drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Drug development and industrial pharmacy - 49(2023), 1 vom: 17. Jan., Seite 52-61 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramkar, Shweta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
57GNO57U7G |
|---|
| Anmerkungen: |
Date Completed 22.03.2023 Date Revised 22.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03639045.2023.2182122 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353099074 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353099074 | ||
| 003 | DE-627 | ||
| 005 | 20231226055227.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03639045.2023.2182122 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM353099074 | ||
| 035 | |a (NLM)36803490 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramkar, Shweta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhanced skin penetration of Finasteride loaded DMSO-liposomes for the treatment of androgenic alopecia |b comparison with conventional liposomes |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2023 | ||
| 500 | |a Date Revised 22.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Long-term treatment with finasteride (FIN) for androgenic alopecia is restricted due to its systemic side effects. To address this problem, DMSO-modified liposomes were prepared in the present study to improve the topical delivery of FIN. DMSO-liposomes were prepared by a modification of the ethanol injection method. It was hypothesized that the permeation-enhancing property of DMSO could promote drug delivery to deeper skin layer where hair follicles are present. Liposomes were optimized by quality by design (QbD) approach and biologically evaluated in a rat model of testosterone-induced alopecia. Optimized DMSO-liposomes were spherical and had mean vesicle size, zeta potential, and entrapment efficiency of 330.1 ± 1.5, -14.52 ± 1.32, and 59.02 ± 1.12%, respectively. Biological evaluation on testosterone-induced alopecia and skin histology shows that follicular density and anagen/telogen (A/T) ratio were increased in rats treated with DMSO-liposomes as compared to FIN-liposomes without DMSO and an alcoholic solution of FIN applied topically. DMSO-liposomes could be promising skin delivery vehicles for FIN or similar drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Androgenic alopecia | |
| 650 | 4 | |a Finasteride | |
| 650 | 4 | |a liposomes | |
| 650 | 4 | |a penetration enhancers | |
| 650 | 4 | |a stratum corneum | |
| 650 | 7 | |a Finasteride |2 NLM | |
| 650 | 7 | |a 57GNO57U7G |2 NLM | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Dimethyl Sulfoxide |2 NLM | |
| 650 | 7 | |a YOW8V9698H |2 NLM | |
| 700 | 1 | |a Kaurav, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Sudheesh, M S |e verfasserin |4 aut | |
| 700 | 1 | |a Pandey, Ravi Shankar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug development and industrial pharmacy |d 1994 |g 49(2023), 1 vom: 17. Jan., Seite 52-61 |w (DE-627)NLM077783093 |x 1520-5762 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2023 |g number:1 |g day:17 |g month:01 |g pages:52-61 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03639045.2023.2182122 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2023 |e 1 |b 17 |c 01 |h 52-61 | ||